Alopecia, Neurologic Defects, and Endocrinopathy Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ANES MCID: ALP041 MIFTS: 51	Alopecia, Neurologic Defects, and Endocrinopathy Syndrome (ANES) Categories: Endocrine diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

MalaCards integrated aliases for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Name: Alopecia, Neurologic Defects, and Endocrinopathy Syndrome ⁵⁶ ⁷³ ²⁹ ¹³ ⁶ ³⁹ ⁷¹

Ane Syndrome ⁵⁶ ⁵⁸ ⁷³

Anes ⁵⁶ ⁷³

Alopecia-Progressive Neurological Defect-Endocrinopathy Syndrome ⁵⁸

Alopecia-Progressive Neurological Defect-Endocrinopathy ⁷³

Alopecia Neurologic Defects and Endocrinopathy Syndrome ³⁶

Endocrine System Diseases ⁷¹

Characteristics:

Orphanet epidemiological data:

⁵⁸

ane syndrome
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide);

OMIM:

⁵⁶

Inheritance:
autosomal recessive

Miscellaneous:
endocrine defects evolve over time
based on report of 5 brothers of arab-moslem descent (last curated february 2015)

HPO:

³¹

alopecia, neurologic defects, and endocrinopathy syndrome:
Inheritance autosomal recessive inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Reproductive diseases Skin diseases Endocrine diseases Mental diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare neurological diseases

Rare infertility disorders

Rare gynaecological and obstetric diseases

Rare skin diseases

Rare endocrine diseases

External Ids:

OMIM ⁵⁶ 612079

KEGG ³⁶ H00621

MeSH ⁴³ D000505 D004700 D009422

UMLS via Orphanet ⁷² C2677535

Orphanet ⁵⁸ ORPHA157954

MedGen ⁴¹ C2677535

UMLS ⁷¹ C0014130 C2677535

Sources

Summaries for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

KEGG : ³⁶ Alopecia neurological defects and endocrinopathy syndrome (ANE syndrome) is an autosomal recessive disease that is clinically heterogeneous. ANE syndrome patients display multiple signs including a varied amount of hair loss, mental retardation, progressive loss of motor ability beginning in the second decade of life, hypogonadism, central adrenal insufficiency, short stature, microcephaly, and several other skeletal and skin abnormalities. The syndrome is caused by decreased expression of the nucleolar protein RBM28, known to be required for biogenesis of the 60S subunit of the ribosome.

MalaCards based summary : Alopecia, Neurologic Defects, and Endocrinopathy Syndrome, also known as ane syndrome, is related to hair-an syndrome and rare hemorrhagic disorder due to an acquired platelet anomaly, and has symptoms including cushingoid facies, pathological conditions, signs and symptoms and breast pain male. An important gene associated with Alopecia, Neurologic Defects, and Endocrinopathy Syndrome is RBM28 (RNA Binding Motif Protein 28), and among its related pathways/superpathways is Ribosome biogenesis in eukaryotes. The drugs Insulin glargine and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and skin, and related phenotypes are intellectual disability and delayed skeletal maturation

UniProtKB/Swiss-Prot : ⁷³ Alopecia, neurologic defects, and endocrinopathy syndrome: Affected individuals have hair loss of variable severity, ranging from complete alopecia to near-normal scalp hair with absence of body hair. All have moderate to severe mental retardation, progressive motor deterioration and central hypogonadotropic hypogonadism with delayed or absent puberty and central adrenal insufficiency. Additional features included short stature, microcephaly, gynecomastia, pigmentary anomalies, hypodontia, kyphoscoliosis, ulnar deviation of the hands, and loss of subcutaneous fat.

More information from OMIM: 612079

Sources

Related Diseases for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Diseases related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 13217)

#	Related Disease	Score
1	hair-an syndrome	12.4
2	rare hemorrhagic disorder due to an acquired platelet anomaly	12.3
3	hemophagocytic syndrome associated with an infection	12.2
4	rare hemorrhagic disorder due to an acquired coagulation factor defect	12.2
5	sickle cell disease associated with an other hemoglobin anomaly	12.2
6	silver-russell syndrome due to an imprinting defect of 11p15	12.2
7	hemolytic anemia due to an erythrocyte nucleotide metabolism disorder	12.2
8	sucking/swallowing disorder associated with an identified syndrome	12.1
9	rare thrombotic disorder due to an acquired platelet anomaly	12.1
10	rare thrombotic disorder due to an acquired coagulation factors defect	12.1
11	systemic inflammatory disease associated with an acquired peripheral neuropathy	12.1
12	hematological disease associated with an acquired peripheral neuropathy	12.1
13	solid tumor associated with an acquired peripheral neuropathy	12.1
14	rare female infertility due to an implantation defect	12.1
15	female infertility due to an implantation defect of genetic origin	12.1
16	rare female infertility due to an anomaly of ovarian function of genetic origin	12.1
17	rare female infertility due to an anomaly of ovarian function	12.1
18	rare female infertility due to an adrenal disorder	12.1
19	rare constitutional hemolytic anemia due to an enzyme disorder	12.1
20	congenital intestinal disease due to an enzymatic defect	12.1
21	schizophrenia	11.8
22	aniridia 1	11.8
23	acanthosis nigricans	11.8
24	anorexia nervosa	11.7
25	acute necrotizing encephalitis	11.7
26	schizophrenia 1	11.6
27	schizophrenia 3	11.6
28	schizophrenia 7	11.6
29	polydactyly, preaxial iii	11.6
30	schizophrenia 18	11.6
31	blood group--ahonen	11.6
32	encephalopathy, acute, infection-induced 4	11.4
33	schizophrenia 8	11.4
34	bile duct cystadenocarcinoma	11.4
35	schizophrenia 5	11.4
36	schizophrenia 9	11.4
37	systemic mastocytosis with associated hematologic neoplasm	11.4
38	schizophrenia 15	11.2
39	schizophrenia 19	11.2
40	aneurysm	11.2
41	diarrhea	11.1
42	migraine with or without aura 1	11.1
43	autoimmune disease	11.1
44	ataxia neuropathy spectrum	11.1
45	immunodeficiency due to a classical component pathway complement deficiency	11.1
46	aortic aneurysm	11.1
47	atrial fibrillation	11.1
48	down syndrome	11.1
49	stroke, ischemic	11.1
50	cardiac arrest	11.1

Comorbidity relations with Alopecia, Neurologic Defects, and Endocrinopathy Syndrome via Phenotypic Disease Network (PDN):

Acute Cystitis

Hypertension, Essential

Graphical network of the top 20 diseases related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Sources

Symptoms & Phenotypes for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Human phenotypes related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

⁵⁸ ³¹ (show all 39)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	intellectual disability ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0001249
2	delayed skeletal maturation ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0002750
3	carious teeth ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000670
4	microcephaly ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000252
5	short stature ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0004322
6	delayed puberty ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000823
7	lipoatrophy ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0100578
8	motor deterioration ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0002333
9	alopecia ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0001596
10	kyphoscoliosis ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0002751
11	multiple joint contractures ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0002828
12	hypodontia ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000668
13	gynecomastia ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000771
14	hyperpigmented nevi ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0007481
15	premature loss of teeth ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0006480
16	growth hormone deficiency ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000824
17	anterior pituitary hypoplasia ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0010627
18	hyperpigmentation of the skin ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000953
19	decreased serum testosterone level ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0040171
20	adrenocorticotropin deficient adrenal insufficiency ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0011735
21	decreased serum insulin-like growth factor 1 ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0030353
22	motor neuron atrophy ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0007373
23	ulnar deviation of the hand ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0009487
24	abnormal response to acth stimulation test ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0031074
25	hypogonadotropic hypogonadism ³¹	frequent (33%)		HP:0000044
26	generalized amyotrophy ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0003700
27	pituitary hypothyroidism ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0008245
28	reduced circulating prolactin concentration ³¹	occasional (7.5%)		HP:0008202
29	flexion contracture ³¹			HP:0001371
30	skeletal muscle atrophy ³¹			HP:0003202
31	melanocytic nevus ³¹			HP:0000995
32	hypogonadotrophic hypogonadism ⁵⁸		Frequent (79-30%)
33	upper motor neuron dysfunction ³¹			HP:0002493
34	hypogonadism ³¹			HP:0000135
35	adrenal insufficiency ³¹			HP:0000846
36	prolactin deficiency ⁵⁸		Occasional (29-5%)
37	central adrenal insufficiency ³¹			HP:0011734
38	reduced subcutaneous adipose tissue ³¹			HP:0003758
39	ulnar deviation of the hand or of fingers of the hand ³¹			HP:0001193

Symptoms via clinical synopsis from OMIM:

⁵⁶

Skeletal Spine:
kyphoscoliosis

Chest Breasts:
gynecomastia

Muscle Soft Tissue:
decreased subcutaneous fat
muscle atrophy

Head And Neck Head:
decreased head circumference

Skeletal:
joint contractures

Skin Nails Hair Hair:
alopecia, variable severity
scalp biopsy shows absence of mature hair follicles

Head And Neck Teeth:
hypodontia
dental caries
early teeth loss

Neurologic Central Nervous System:
upper motor neuron dysfunction
mental retardation, moderate to severe
motor deterioration in second decade
lower motor neuron dysfunction
brain mri shows hypoplastic pituitary

Endocrine Features:
central adrenal insufficiency
hypogonadotropic hypogonadism
low testosterone levels
absent or delayed puberty
low insulin-like growth factor-1 (igf1) concentration
more

Skin Nails Hair Skin:
pigmented nevi
hyperpigmentation in flexure areas

Skeletal Hands:
ulnar deviation of the hands

Clinical features from OMIM:

612079

UMLS symptoms related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

cushingoid facies, pathological conditions, signs and symptoms, breast pain male

Sources

Drugs & Therapeutics for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Drugs for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Insulin glargine

Approved

Phase 4

160337-95-1

Insulin aspart

Approved

Phase 4

116094-23-6

16132418

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

5754

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Epinephrine

Approved, Vet_approved

Phase 4

51-43-4

5816

Racepinephrine

Approved

Phase 4

329-65-7

838

Norepinephrine

Approved

Phase 4

51-41-2

439260

Metyrapone

Approved, Investigational

Phase 4

54-36-4

4174

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

5743

Insulin degludec, insulin aspart drug combination

Phase 4

Insulin, Long-Acting

Phase 4

Antidepressive Agents

Phase 4

Hydrocortisone 17-butyrate 21-propionate

Phase 4

Hydrocortisone hemisuccinate

Phase 4

Antimetabolites

Phase 4

Epinephryl borate

Phase 4

Serotonin and Noradrenaline Reuptake Inhibitors

Phase 4

Serotonin Uptake Inhibitors

Phase 4

Hypoglycemic Agents

Phase 4

Sodium-Glucose Transporter 2 Inhibitors

Phase 4

5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)...

Phase 4

Serotonin

Investigational, Nutraceutical

Phase 4

50-67-9

5202

Metformin

Approved

Phase 3

657-24-9

14219 4091

Zinc

Approved, Investigational

Phase 3

7440-66-6

32051

Glimepiride

Approved

Phase 3

93479-97-1

3476

Saxagliptin

Approved

Phase 3

361442-04-8

11243969

Acarbose

Approved, Investigational

Phase 3

56180-94-0

441184

Mannitol

Approved, Investigational

Phase 3

69-65-8

6251 453

Glucagon

Approved

Phase 3

16941-32-5

Dulaglutide

Approved, Investigational

Phase 3

923950-08-7

Calcium carbonate

Approved, Investigational

Phase 3

471-34-1

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Linagliptin

Approved

Phase 3

668270-12-0

10096344

Naltrexone

Approved, Investigational, Vet_approved

Phase 3

16590-41-3

5360515

Nutmeg

Approved

Phase 3

Bupropion

Approved

Phase 3

34911-55-2, 34841-39-9

444

tannic acid

Approved

Phase 3

1401-55-4

Benzocaine

Approved, Investigational

Phase 3

94-09-7, 1994-09-7

2337

Glycine

Approved, Nutraceutical, Vet_approved

Phase 3

56-40-6

750

gastric inhibitory polypeptide

Investigational

Phase 3

100040-31-1

Antihypertensive Agents

Phase 3

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,...

Phase 3

Insulin, Short-Acting

Phase 3

Anti-Arrhythmia Agents

Phase 3

Sitagliptin Phosphate

Phase 3

Angiotensin Receptor Antagonists

Phase 3

Angiotensin-Converting Enzyme Inhibitors

Phase 3

Growth Hormone-Releasing Hormone

Phase 3

Glucagon-Like Peptide 1

Phase 3

Interventional clinical trials:

(show top 50) (show all 251)

#	Name	Status	NCT ID	Phase	Drugs
1	Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Children Growth Hormone Deficiency: A Multicenter, Randomized, Parallel, Dose-control Clinical Trial II	Unknown status	NCT02908958	Phase 4
2	Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Open-label, Phase IV Clinical Trial With Different Administration Dosage of PEG Somatropin	Unknown status	NCT03249480	Phase 4
3	Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Randomized, Open-label, Parallel Phase IV Clinical Trial With Different Administration Frequency of PEG Somatropin	Unknown status	NCT02976675	Phase 4
4	Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)	Completed	NCT01806298	Phase 4	Saizen® solution for injection (referred as Saizen®)
5	Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia	Completed	NCT00140413	Phase 4	Nutropin AQ
6	The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia	Completed	NCT02192450	Phase 4	Insulin aspart/glargine;Insulin aspart/degludec
7	Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.	Recruiting	NCT03491696	Phase 4	Metyrapone
8	Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism	Active, not recruiting	NCT01848171	Phase 4	L-thyroxine
9	The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study	Active, not recruiting	NCT01831869	Phase 4	L-thyroxine
10	The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure	Not yet recruiting	NCT04071626	Phase 4	Ertugliflozin 5 mg;Placebo oral tablet
11	Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency	Terminated	NCT01698944	Phase 4	somatropin
12	Placebo Controlled Trial on the Efficacy of Growth Hormone Replacement Therapy in Patients With Growth Hormone Deficiency After Traumatic Brain Injury.	Terminated	NCT00555009	Phase 4	Genotropin;Placebo
13	Head Trauma With Traumatic Brain Injury (TBI): A Multicenter, Phase IV Study to Evaluate the Effects of Genotropin in Adult Patients With Growth Hormone Deficiency (GHD) Caused by Trauma and/or Head Injury	Terminated	NCT00638053	Phase 4
14	Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study.	Completed	NCT00163215	Phase 3	Somatropin
15	Extended Clinical Study of LY137998 [Somatropin (Recombinant DNA Origin)] in Adults With Growth Hormone Deficiency	Completed	NCT00191360	Phase 3	Somatropin
16	Phase III of the Comparative Study on the Efficacy and Safety of Recombinant Somatropin Administered to Patients With Adult Growth Hormone Deficiency	Completed	NCT02693522	Phase 3	somatropin;Eutropin
17	Investigation of the Efficacy and Safety of NN-220 for 48 Weeks in Adults With Growth Hormone Deficiency	Completed	NCT00184743	Phase 3	somatropin
18	Effect of Two Years of Treatment With Norditropin® SimpleXx® on Bone Mineral Density in Young Adults With Childhood-Onset Growth Hormone Deficiency	Completed	NCT00184678	Phase 3	somatropin
19	Effect of Growth Hormone in Children With Growth Hormone Deficiency and Idiopathic Short Stature	Completed	NCT00262249	Phase 3	somatropin
20	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.	Completed	NCT00294619	Phase 3	growth hormone
21	Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency	Completed	NCT00519558	Phase 3	somatropin
22	Randomized Controlled Trial Comparing the Metabolic Efficiency of Allogeneic Pancreatic Islet Transplantation to Intensive Insulin Therapy for the Treatment of Type 1 Diabetes	Completed	NCT01148680	Phase 3
23	A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency	Completed	NCT00596037	Phase 3	Growth hormone - LB03002
24	Efficacy and Safety of a High Dosage Compared to the Label Dosage of Humatrope in Early Pubertal Stage Children With Growth Hormone Deficiency	Completed	NCT00191165	Phase 3	Somatropin;Somatropin
25	A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise	Completed	NCT00736879	Phase 3	Dapagliflozin;Placebo
26	Norditropin® and Norditropin® Cartridges: An Open-Label, Randomized, Comparative Safety and Efficacy Trial in Children With Growth Hormone Deficiency	Completed	NCT01502124	Phase 3	somatropin;somatropin
27	Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men	Completed	NCT02081300	Phase 3	Oral testosterone undecanoate, LPCN 1021;Topical testosterone gel 1.62 %
28	A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency	Completed	NCT03075644	Phase 3	somapacitan;Norditropin
29	fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD	Completed	NCT03305016	Phase 3	TransCon hGH
30	A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency	Completed	NCT02382939	Phase 3	somapacitan;somatropin
31	A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin	Completed	NCT01841697	Phase 3	Omarigliptin;Sitagliptin;Placebo to omarigliptin;Placebo to Sitagliptin;Open-label Metformin;Open-label Glimepiride
32	A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control	Completed	NCT00859898	Phase 3	Dapagliflozin;Metformin XR;Metformin XR;dapagliflozin matching Placebo;metformin HCl Modified Release matching Placebo
33	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone	Completed	NCT00528879	Phase 3	Dapagliflozin;Placebo;Metformin
34	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)	Completed	NCT01137474	Phase 3	Dapagliflozin;Placebo-matching dapagliflozin
35	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication	Completed	NCT01195662	Phase 3	Dapagliflozin;Placebo matching Dapagliflozin
36	A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)	Completed	NCT02781727	Phase 3	Once weekly subcutaneous injection of TransCon hGH;Once daily subcutaneous injection of Genotropin
37	A Randomised, Open-label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety for 12 Months of Zomacton to Genotropin in Children With Idiopathic Growth Hormone Deficiency	Completed	NCT00884000	Phase 3	Genotropin;Zomacton
38	A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period	Completed	NCT02229851	Phase 3	somapacitan;somatropin;placebo
39	Pegylated Somatropin in the Treatment of Children With Growth Hormone Deficient：A Multicenter, Randomized, Open-label, Controlled Phase Ⅲ Clinical Trial	Completed	NCT01495468	Phase 3
40	A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control	Completed	NCT02273050	Phase 3	Saxagliptin 5 mg;Placebo 5 mg for Saxagliptin;Placebo 500 mg for metformin (with titration);Metformin 500 mg with titration
41	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control	Completed	NCT01814748	Phase 3	Omarigliptin;Placebo to omarigliptin;Metformin
42	Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)	Completed	NCT02558829	Phase 3	Macimorelin;Insulin
43	A Phase III, Multicentric, Open-label, Randomised, Comparative, Parallel Group Study of (GHRH + Arginine) Combination Test vs. Insulin Tolerance Test (ITT) in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)	Completed	NCT01060488	Phase 3
44	Efficacy and Safety of CinnaGen Recombinant Human Growth Hormone (CinnaTropin®) in Comparison With Novo Nordisk Growth Hormone (Nordilet®) Product in Pre-Pubertal Children With Idiopathic Growth Hormone Deficiency (IGHD)	Completed	NCT03223025	Phase 3	CinnaTropin®;Nordilet®
45	A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS)	Completed	NCT00109733	Phase 3
46	A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency	Completed	NCT03874013	Phase 3	MOD-4023;Genotropin
47	A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Chinese Subjects in China With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination With Metformin	Completed	NCT02104804	Phase 3	Saxagliptin 5mg;Placebo for Saxagliptin
48	The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)	Recruiting	NCT04255433	Phase 3	Tirzepatide;Dulaglutide
49	The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China	Recruiting	NCT04326374	Phase 3	TransCon hGH;daily hGH
50	Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)	Active, not recruiting	NCT03730662	Phase 3	Tirzepatide;Insulin Glargine

Search NIH Clinical Center for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Sources

Genetic Tests for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Genetic tests related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

#	Genetic test	Affiliating Genes
1	Alopecia, Neurologic Defects, and Endocrinopathy Syndrome ²⁹	RBM28

Sources

Anatomical Context for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

MalaCards organs/tissues related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

⁴⁰

Testes, Bone, Skin, Brain, Heart, Pituitary, Thyroid

Sources

Publications for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Articles related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

(show top 50) (show all 132)

#	Title	Authors	PMID	Year
1	Alopecia, neurological defects, and endocrinopathy syndrome caused by decreased expression of RBM28, a nucleolar protein associated with ribosome biogenesis. ⁵⁶ ⁶	Nousbeck J...Sprecher E	18439547	2008
2	ANE syndrome caused by mutated RBM28 gene: a novel etiology of combined pituitary hormone deficiency. ⁵⁶	Spiegel R...Tenenbaum-Rakover Y	20231366	2010
3	First Reported Cochlear Implantation in a Child with Total Artificial Heart. ⁶¹	Buyukatalay ZC...Meco C	32281525	2020
4	Aggregate Impact of Anomalous Noise Events on the WASN-Based Computation of Road Traffic Noise Levels in Urban and Suburban Environments. ⁶¹	Alias F...Socoro JC	31979126	2020
5	Anticipated Negative Emotions Effect on Incident Involvement Among Civil Pilots. ⁶¹	Wang H...Ji M	31426892	2019
6	New binding modes for CSe: coinage metal coordination to a tungsten selenocarbonyl complex. ⁶¹	Frogley BJ...Watson LJ	31372618	2019
7	Hemilabile bonding of 1-oxa-4,7-dithiacyclononane in cyclometallated palladium(ii) complexes. ⁶¹	Janzen DE...da Silva Filho DA	31294426	2019
8	MAPK inhibition and growth hormone: a promising therapy in XLH. ⁶¹	Fuente R...Santos F	30974062	2019
9	Acute Neurologic Injury in Children Admitted to the Cardiac Intensive Care Unit. ⁶¹	Bell JL...Sanchez-de-Toledo J	30682351	2019
10	A WASN-Based Suburban Dataset for Anomalous Noise Event Detection on Dynamic Road-Traffic Noise Mapping. ⁶¹	Alsina-Pages RM...Socoro JC	31151261	2019
11	Alleviating the nurse faculty shortage: designating and preparing the academic nurse educator as an advanced practice registered nurse. ⁶¹	Gazza EA	30380167	2019
12	Network Effects in Blau Space: Imputing Social Context from Survey Data. ⁶¹	McPherson M...Smith JA	31482131	2019
13	Impact of spinal needle design and approach to postdural puncture headache and spinal anesthesia failure in obstetrics. ⁶¹	Batova R...Georgiev S	31268266	2019
14	A new neurostimulator guided technique of rectus sheath block: study of feasibility and local anesthetic spread in children. ⁶¹	Albokrinov AA...Fesenko UA	31268267	2019
15	Ascophyllum nodosum extract biostimulants and their role in enhancing tolerance to drought stress in tomato plants. ⁶¹	Goni O...O'Connell S	29501894	2018
16	Addition of dithi(ol)anylium tetrafluoroborates to α,β-unsaturated ketones. ⁶¹	Huang YC...Brase S	29623112	2018
17	Combined Enteral and Parenteral Glutamine Supplementation in Endotoxemic Swine: Effects on Portal and Systemic Circulation Levels. ⁶¹	Stavrou G...Kotzampassi K	30184534	2018
18	Anesthetic Implications of Superior Vena Cava Syndrome in Interventional Radiology: A Case Report. ⁶¹	Dishman D	31573505	2017
19	On the Impact of Anomalous Noise Events on Road Traffic Noise Mapping in Urban and Suburban Environments. ⁶¹	Orga F...Alsina-Pages RM	29295492	2017
20	Development of Pediatric Neurologic Emergency Life Support Course: A Preliminary Report. ⁶¹	Haque A...Ahmed K	26855341	2017
21	Ultrastructural study of the neural microcircuits in the sensory epithelium of the paratympanic organ of the chicken. ⁶¹	Giannessi F...Ruffoli R	28715600	2017
22	Quasiparticle and optical properties of strained stanene and stanane. ⁶¹	Lu P...Wang S	28634387	2017
23	Reversible mechanical protection: building a 3D "suit" around a T-shaped benzimidazole axle. ⁶¹	Zhu K...Loeb SJ	28626559	2017
24	[General Anesthesia for Septal Myectomy in a Patient with Noonan Syndrome, Severe Hypertrophic Obstructive Cardiomyopathy and Right Ventricular Outflow Tract Obstruction]. ⁶¹	Tanaka Y...Shindo K	30382642	2017
25	[Risk Factors for the Postsurgical Hoarseness Contribution of the Intubation Device]. ⁶¹	Matsuo K...Amaya F	30382636	2017
26	[A Case of Rocuronium-induced Anaphylaxis in a Man with Kounis Syndrome in which Basophil Activation Test was Valuable in Determining the Causative Agent]. ⁶¹	Sakamoto S...Saito S	30382647	2017
27	[A Perspective View on Peripheral Nerve Block of the Future: Preface and Comments]. ⁶¹	Kawamata M	30380212	2017
28	Effectively explore metastable states of proteins by adaptive nonequilibrium driving simulations. ⁶¹	Wan B...Zhou X	28415335	2017
29	[Influence of Propofol and Remifentanil on Pupillary Light Reflex Assessed by a Hand-held Point-and-shoot Pupillometer]. ⁶¹	Hoshi T	30380283	2017
30	[Successful Awake Intubation with Airway Scope? for a Difficult Airway Patient with Enormous Angioma Protruding out of the Mouth]. ⁶¹	Ueda S...Otake H	30380273	2017
31	[A Case of Persistent Dysesthesia after Uneventful Spinal Anesthesia with Bupivacaine]. ⁶¹	Sakai M...Harada T	30380257	2017
32	[History of Tracheal Intubation: 1. First Application of Tracheal Intubation during General Anesthesia]. ⁶¹	Asai T	30380267	2017
33	[Anesthesia and Anti-cancer Therapeutic Agents]. ⁶¹	Ozato S...Yokota M	30351801	2016
34	[Preoperatively Administered Drugs and Anesthetic Consideration for a Parturient Requiring Cesarean Section]. ⁶¹	Sumikura H	30351803	2016
35	Clinical effect of ablative fractional laser-assisted topical anesthesia on human skin: A randomized pilot study. ⁶¹	Tian T...Li Y	27419471	2016
36	Adverse neuropsychological effects associated with cumulative doses of corticosteroids to treat childhood acute lymphoblastic leukemia: A literature review. ⁶¹	Pepin AJ...Sultan S	27823641	2016
37	Tuning the Luminescent Properties of a Ag/Au Tetranuclear Complex Featuring Metallophilic Interactions via Solvent-Dependent Structural Isomerization. ⁶¹	Donamaria R...Olmos ME	27767312	2016
38	Metal ion-modulated self-assembly of pseudo-suit[3]anes using crown ether-based terpyridine metalloprisms. ⁶¹	Wang YC...Chan YT	27711374	2016
39	[Blood Transfusion in a Patient with Severe Anemia and Immunoglobulin A Deficiency during an Emergency Total Hysterectomy on a Holiday]. ⁶¹	Hayasi T...Kawasaki T	30358287	2016
40	Prospective, randomized, placebo-controlled trial evaluating the efficacy and safety of propofol sedation by anesthesiologists and gastroenterologist-led teams using computer-assisted personalized sedation during upper and lower gastrointestinal endoscopy. ⁶¹	Kashiwagi K...Ogata H	27176122	2016
41	[Refractory Hypotension Induced by Continuous Phonation during Spinal Anesthesia in a Patient Suffering from Severe Aortic Stenosis.] ⁶¹	Nakanishi K...Nagaro T	30351601	2016
42	[Effect of Preoperative Oral Rehydration on the Hypotension during Spinal Anesthesia.] ⁶¹	Itoh S...Okamoto H	30351587	2016
43	[Laparoscopi Surgery and Anesthetic Management for Infants and Children]. ⁶¹	Kamata M	30358319	2016
44	12th WINFOCUS world congress on ultrasound in emergency and critical care. ⁶¹	Acar Y...Mazlan MZ	27604617	2016
45	[Satisfactory Sedation for a Morbidly Obese Woman by Dexmedetomidine Dosed on the Basis of Total Body Weight under Spinal Anesthesia ; A Case Report]. ⁶¹	Mori Y...Ohki K	30358307	2016
46	[The Effectiveness of Two Anesthesia Machines in the Water Generation of the Anesthesia Circuit during the Prolonged Low Flow Desflurane Anesthesia]. ⁶¹	Obata R...Obata Y	30358309	2016
47	[A Multicenter Questionnaire Survey of Postoperative Delirium -National Hospital Organization, Surgery and Anesthesia Network Group-]. ⁶¹	Siuciuno T...Hirao M	30358310	2016
48	[A Trained-in-Japan Anesthesiologist Going Through Anesthesia Training in the United States : What Adjustments Should be Made for Upcoming Renewal in Anesthesia Board Certification in Japan?]. ⁶¹	Morita Y...Nomoto K	30358312	2016
49	[Effect of Transcutaneous Acupoint Electrical Stimulation on Propofol Usage in Closed-loop Anes- thesia Delivery System in Pediatric Cardiac Surgery]. ⁶¹	Jin N...Zhu JC	30640984	2016
50	Comparative Transcriptome Analysis of Two Ascophyllum nodosum Extract Biostimulants: Same Seaweed but Different. ⁶¹	Goni O...O'Connell S	27010818	2016

Sources

Genes for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Genes related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	RBM28	RNA Binding Motif Protein 28	Protein Coding	1718.51	Molecular basis known ⁵⁶ Pathogenic ⁶ Causative germline mutation (loss of function) ⁵⁸ Causative variation ⁷³ Genetic Tests ²⁹ Unconfirmed association ⁵⁶ GeneCards inferred via : Disorders Variants (show sections)	18439547

Sources

Variations for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

ClinVar genetic disease variations for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

⁶ ‎‎ ‎‎ ‎‎

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	RBM28	NM_018077.3(RBM28):c.541+1del	deletion	Pathogenic	802364		7:127978303-127978303	7:128338249-128338249
2	RBM28	NM_018077.3(RBM28):c.1052T>C (p.Leu351Pro)	SNV	Pathogenic	732	rs118204055	7:127970949-127970949	7:128330896-128330896
3	RBM28	NM_018077.3(RBM28):c.946G>T (p.Ala316Ser)	SNV	Likely pathogenic	802363		7:127975597-127975597	7:128335543-128335543

UniProtKB/Swiss-Prot genetic disease variations for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

⁷³

#	Symbol	AA change	Variation ID	SNP ID
1	RBM28	p.Leu351Pro	VAR_045655	rs118204055

Sources

Expression for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Search GEO for disease gene expression data for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome.

Sources

Pathways for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Pathways related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome according to KEGG:

³⁶

#	Name	Kegg Source Accession
1	Ribosome biogenesis in eukaryotes	hsa03008

Sources

GO Terms for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Sources

Sources for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Alopecia, Neurologic Defects, and Endocrinopathy Syndrome (ANES)

Aliases & Classifications for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

MalaCards integrated aliases for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Characteristics:

Orphanet epidemiological data:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Related Diseases for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Diseases related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Alopecia, Neurologic Defects, and Endocrinopathy Syndrome via Phenotypic Disease Network (PDN):

Graphical network of the top 20 diseases related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Symptoms & Phenotypes for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Human phenotypes related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

UMLS symptoms related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Drugs & Therapeutics for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Drugs for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Genetic tests related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Anatomical Context for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

MalaCards organs/tissues related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Publications for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Articles related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Genes for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Genes related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome (1 elite genes):

Variations for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

ClinVar genetic disease variations for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

UniProtKB/Swiss-Prot genetic disease variations for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome:

Expression for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Pathways for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Pathways related to Alopecia, Neurologic Defects, and Endocrinopathy Syndrome according to KEGG:

GO Terms for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome

Sources for Alopecia, Neurologic Defects, and Endocrinopathy Syndrome